CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||20 mg/1 mL & 40 mg/2 mL|
|Indication||Peripheral T-Cell Lymphoma (PTCL)|
|Funding Request||for the treatment of patients with relapsed or refractory PTCL|
|Pre Noc Submission||Yes|
|NOC Date||October 26, 2018|
|Manufacturer||Servier Canada Inc.|
|Sponsor||Servier Canada Inc.|
|Submission Date||June 1, 2018|
|Submission Deemed Complete||June 8, 2018|
|Prioritization Requested||Requested and Not Granted|
|Stakeholder Input Deadline ‡||June 15, 2018|
|Check-point meeting||August 7, 2018|
|pERC Meeting||January 17, 2019|
|Initial Recommendation Issued||January 31, 2019|
|Feedback Deadline ‡||February 14, 2019|
|pERC Reconsideration Meeting||March 21, 2019|
|Final Recommendation Issued||April 4, 2019|
|Notification to Implement Issued||April 22, 2019|
|Clarification||The timeline of the review was temporarily stopped, pending receipt of the additional information. The timeline of the review has resumed as the additional information has now been provided.|
|Therapeutic Area||Peripheral T-Cell Lymphoma (PTCL)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.